Cencora, Inc. (NYSE:COR) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP cut its stake in Cencora, Inc. (NYSE:COR - Free Report) by 7.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 237,450 shares of the company's stock after selling 18,016 shares during the quarter. Bridgewater Associates LP owned approximately 0.12% of Cencora worth $53,445,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Lake Street Advisors Group LLC grew its holdings in Cencora by 1.3% in the 3rd quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company's stock valued at $769,000 after buying an additional 43 shares in the last quarter. Financial Advocates Investment Management boosted its position in shares of Cencora by 4.7% during the 2nd quarter. Financial Advocates Investment Management now owns 978 shares of the company's stock valued at $220,000 after acquiring an additional 44 shares during the last quarter. Venturi Wealth Management LLC grew its holdings in shares of Cencora by 1.0% in the third quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company's stock valued at $1,001,000 after purchasing an additional 46 shares during the period. Prime Capital Investment Advisors LLC increased its position in Cencora by 1.2% during the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company's stock worth $848,000 after purchasing an additional 46 shares during the last quarter. Finally, Checchi Capital Advisers LLC raised its stake in Cencora by 2.2% during the second quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company's stock worth $499,000 after purchasing an additional 48 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Trading Up 1.7 %

NYSE COR opened at $248.40 on Wednesday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The firm has a market cap of $48.95 billion, a price-to-earnings ratio of 33.08, a PEG ratio of 1.63 and a beta of 0.44. The firm has a 50 day simple moving average of $233.56 and a 200-day simple moving average of $232.01. Cencora, Inc. has a one year low of $195.83 and a one year high of $251.56.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be paid a $0.55 dividend. This is an increase from Cencora's previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora's payout ratio is 29.29%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Evercore ISI raised their price target on shares of Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. UBS Group raised their target price on Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Barclays upped their price target on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Robert W. Baird raised their price objective on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their target price on shares of Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a research report on Wednesday, August 21st. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $271.20.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 50,000 shares of the business's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now directly owns 326,557 shares of the company's stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 93,018 shares of company stock valued at $22,478,942. 15.80% of the stock is currently owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.